

S5 Table. Included 41 studies [1-41]

1. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. *J Can Assoc Radiol.* 1981;32:164-5.
2. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil: an Eastern Cooperative Oncology Group study. *J Clin Oncol.* 1985;3:373-8.
3. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. *J Natl Cancer Inst.* 1988;80:751-5.
4. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. *J Gastrointest Surg.* 1998;2:159-66.
5. Conroy T, Paillet B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer: a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. *J Clin Oncol.* 2005;23:1228-36.
6. Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. *J Clin Oncol.* 2007;25:1665-9.
7. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCO/SFRO study. *Ann Oncol.* 2008;19:1592-9.
8. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. *Jpn J Clin Oncol.* 2010;40:573-9.
9. Loehrer PJ, Sr., Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. *J Clin Oncol.* 2011;29:4105-12.
10. Sahara K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. *World J Surg.* 2011;35:1580-9.
11. Sahara K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, et al. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. *Surgery.* 2011;149:311-20.
12. Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. *Surgery.* 2012;152:851-62.
13. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. *Br J Cancer.* 2012;106:1934-9.
14. Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the

-
- treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). *Cancer Chemother Pharmacol*. 2012;69:1197-204.
15. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. *Br J Cancer*. 2013;108:766-70.
 16. Ueno M, Okusaka T, Mizusawa J, Takashima A, Morizane C, Ikeda M, et al. Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805). *J Clin Oncol*. 2012;30(15 Suppl):4031.
 17. Stein S, Cong X, Yao X, Hahn C, Li J, Kortmansky JS, et al. Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC). *J Clin Oncol*. 2015;33(15 Suppl):e15274.
 18. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. *JAMA*. 2016;315:1844-53.
 19. Wagener DJ, van Hoesel QG, Yap SH, Hoogenraad WJ, Wobbes T, Strijk SP. Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer. *Cancer Chemother Pharmacol*. 1989;25:131-4.
 20. Wagener DJ, Hoogenraad WJ, Rougier P, Lusinchi A, Taal BG, Veenhof CH, et al. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. *Eur J Cancer*. 1996;32A:1310-3.
 21. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. *J Surg Oncol*. 2002;81:138-43.
 22. Al-Sukhun S, Zalupski MM, Ben-Josef E, Vaitkevicius VK, Philip PA, Soulen R, et al. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. *Am J Clin Oncol*. 2003;26:543-9.
 23. Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, et al. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. *Am J Clin Oncol*. 2005;28:345-50.
 24. Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, et al. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer. *Tumori*. 2006;92:481-6.
 25. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2007;68:809-16.
 26. Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, et al. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. *Br J Cancer*. 2007;97:464-71.
 27. Moureau-Zabotto L, Phelip JM, Afchain P, Mineur L, Andre T, Vendrely V, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with
-

locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. *J Clin Oncol*. 2008;26:1080-5.

28. Marti JL, Hochster HS, Hiottis SP, Donahue B, Ryan T, Newman E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. *Ann Surg Oncol*. 2008;15:3521-31.

29. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. *J Surg Oncol*. 2010;101:587-92.

30. Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, et al. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. *Cancer Chemother Pharmacol*. 2010;66:527-34.

31. Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, et al. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. *Int J Radiat Oncol Biol Phys*. 2011;81:e749-57.

32. Crane CH, Varadhachary GR, Yordy JS, Staerckel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. *J Clin Oncol*. 2011;29:3037-43.

33. Milandri C, Polico R, Garcea D, Passardi A, Gardini A, Romeo A, et al. GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. *Hepatogastroenterology*. 2011;58:599-603.

34. Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, et al. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. *Br J Cancer*. 2012;106:61-9.

35. Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, et al. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. *Cancer Chemother Pharmacol*. 2012;70:381-9.

36. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. *Cancer*. 2013;119:277-84.

37. Mukherjee S, Hurt C, Griffiths G, Bridgewater JA, Crosby T, Falk S, et al. SCALOP: results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC). *J Clin Oncol*. 2013;31(4 Suppl):LBA146.

38. Youl M, Hashem S, Brade A, Cummings B, Dawson LA, Gallinger S, et al. Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer. *Clin Oncol (R Coll Radiol)*. 2014;26:203-9.

39. Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*.

2014;88:837-44.

40. Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, et al. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. *World J Gastroenterol.* 2014;20:13987-92.

41. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. *Cancer.* 2015;121:1128-37.
